Prime Medicine, Inc. (NYSE:PRME) Receives $13.38 Consensus Price Target from Analysts
Shares of Prime Medicine, Inc. (NYSE:PRME – Get Free Report) have been given a consensus recommendation of “Buy” by the nine analysts that are covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year […]
Shares of Prime Medicine, Inc. (NYSE:PRME – Get Free Report) have been given a consensus recommendation of “Buy” by the nine analysts that are covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year […]